Daiichi Sankyo, Innovent Sign Exclusive Promotion Agreement for Quizartinib in Mainland China
On August 10, Daiichi Sankyo and Innovent Biologics announced an exclusive promotion agreement for quizartinib hydrochloride tablets (brand name Weifutai®) in mainland China. Under the agreement, Daiichi Sankyo will be responsible for the clinical development, manufacturing, and supply of the drug, while Innovent will obtain exclusive promotion rights for the product in China and lead its promotion in the Chinese market.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 80% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.